SRPK1 and cancer: Notably, inhibiting SRPK1 altered the splicing program to produce the antagonistic isoform of PD-1, boosting T-cell destruction of cancer cells, and implying the potential application of small molecules targeting SRPK1 as innovative pharmacological immunotherapies (62).